FIELD: biotechnology.
SUBSTANCE: group of inventions relates to immunology. Disclosed are an antibody or an antigen-binding fragment thereof, specifically binding to DLL3, antibody conjugate, a pharmaceutical composition for treating DLL3-associated cancer, coding a recombinant nucleic acid molecule, an expression vector and a host cell for expressing a recombinant nucleic acid molecule, a DLL3 detection kit.
EFFECT: disclosed immunoglobulins selectively bind DLL3, have affinity in the subnanomolar range and can be used in a method of treating DLL3-associated cancer and a method for detecting DLL3 protein levels in a biological sample.
24 cl, 8 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
